Prosetta Biosciences, Inc.
Prosetta Biosciences is a San Francisco-based biotechnology company focused on creating innovative therapeutics for diseases by identifying and advancing novel small molecules that modulate the assembly of multi-protein complexes within cells. Their technology aims to work in tandem with the body's regulatory mechanisms to restore molecular homeostasis, offering a new strategy for treating various diseases including infectious, degenerative, and neurodegenerative disorders.
Industries
Nr. of Employees
small (1-50)
Prosetta Biosciences, Inc.
Patents
Products
Cell-free protein synthesis and assembly screening platform
A converted academic cell-free protein synthesis and assembly (CFPSA) assay into a moderate-throughput screening platform for identifying small molecules that modulate multiprotein assembly.
Hit-finder assembly-modulator compound collection
A curated collection of structurally diverse small molecules (reported ~300) derived from screening that share assembly-modulating properties and are used to probe host assembly pathways and advance lead series.
Pan-respiratory antiviral program (lead series)
Discovery and preclinical advancement of small-molecule chemotypes active across multiple virus families that cause human respiratory disease; reported activity in human airway epithelial cultures and animal models.
HIV assembly-modulation program
Preclinical discovery of multiple small-molecule chemotypes that target host-dependent steps in HIV capsid assembly or post-entry capsid disassembly, producing effects such as redirected proteasomal degradation, release of non-infectious particles, or blocking infection prior to gene expression.
Neuroscience programs (ALS, Alzheimer’s, Parkinson’s)
Application of assembly-modulating small molecules to cellular and animal models of neurodegenerative disease, including compounds that relocalize TDP-43, reduce tau hyperphosphorylation, or modulate alpha-synuclein assembly; includes development of peripheral biomarker assays for ALS.
Oncology pan-cancer assembly-modulator program
Discovery and preclinical exploration of small-molecule series with reported anti-proliferative activity across a broad panel of cancer cell types.
Cell-free protein synthesis and assembly screening platform
A converted academic cell-free protein synthesis and assembly (CFPSA) assay into a moderate-throughput screening platform for identifying small molecules that modulate multiprotein assembly.
Hit-finder assembly-modulator compound collection
A curated collection of structurally diverse small molecules (reported ~300) derived from screening that share assembly-modulating properties and are used to probe host assembly pathways and advance lead series.
Pan-respiratory antiviral program (lead series)
Discovery and preclinical advancement of small-molecule chemotypes active across multiple virus families that cause human respiratory disease; reported activity in human airway epithelial cultures and animal models.
HIV assembly-modulation program
Preclinical discovery of multiple small-molecule chemotypes that target host-dependent steps in HIV capsid assembly or post-entry capsid disassembly, producing effects such as redirected proteasomal degradation, release of non-infectious particles, or blocking infection prior to gene expression.
Neuroscience programs (ALS, Alzheimer’s, Parkinson’s)
Application of assembly-modulating small molecules to cellular and animal models of neurodegenerative disease, including compounds that relocalize TDP-43, reduce tau hyperphosphorylation, or modulate alpha-synuclein assembly; includes development of peripheral biomarker assays for ALS.
Oncology pan-cancer assembly-modulator program
Discovery and preclinical exploration of small-molecule series with reported anti-proliferative activity across a broad panel of cancer cell types.
Services
Research collaborations and partnerships to advance discovery and preclinical development of assembly-modulating small-molecule programs.
Research collaborations and partnerships to advance discovery and preclinical development of assembly-modulating small-molecule programs.
Expertise Areas
- Host-targeted small-molecule drug discovery
- Cell-free assay development and screening
- Proteomics-driven target identification
- Preclinical in vitro and in vivo validation
Key Technologies
- Cell-free protein synthesis and assembly (CFPSA)
- Moderate-throughput small-molecule screening
- Drug-resin affinity chromatography (DRAC)
- Mass spectrometry proteomics (MS-MS)
News & Updates
Prosetta and its collaborators at the Mayo Clinic and the Gladstone Foundation, presented a poster at the Target ALS annual meeting 2025 demonstrating the efficacy of Prosetta compound PAV-615 on the c9orf72 repeat expansion mouse model and in iPSC-derived motor neurons from ALS patients.
A detailed story about the ALS assembly modulator signature in blood cells and its implications.
Prosetta was featured in drug discovery news for its advancements.
Prosetta identified compounds that reduce tau hyperphosphorylation in Alzheimer’s models, targeting oxidized MIF.
Prosetta is the only biotech company in the Scripps Center for Pandemic Preparedness.
Prosetta’s oncology research identified small molecules with efficacy against multiple cancers.
Prosetta and its collaborators at the Mayo Clinic and the Gladstone Foundation, presented a poster at the Target ALS annual meeting 2025 demonstrating the efficacy of Prosetta compound PAV-615 on the c9orf72 repeat expansion mouse model and in iPSC-derived motor neurons from ALS patients.
A detailed story about the ALS assembly modulator signature in blood cells and its implications.
Prosetta was featured in drug discovery news for its advancements.
Prosetta identified compounds that reduce tau hyperphosphorylation in Alzheimer’s models, targeting oxidized MIF.
Prosetta is the only biotech company in the Scripps Center for Pandemic Preparedness.
Prosetta’s oncology research identified small molecules with efficacy against multiple cancers.